Fate Therapeutics (FATE) Debt to Equity (2016 - 2019)
Historic Debt to Equity for Fate Therapeutics (FATE) over the last 8 years, with Q3 2019 value amounting to $0.05.
- Fate Therapeutics' Debt to Equity fell 3918.4% to $0.05 in Q3 2019 from the same period last year, while for Sep 2019 it was $0.05, marking a year-over-year decrease of 3918.4%. This contributed to the annual value of $0.09 for FY2018, which is 5165.1% down from last year.
- According to the latest figures from Q3 2019, Fate Therapeutics' Debt to Equity is $0.05, which was down 3918.4% from $0.12 recorded in Q2 2019.
- Fate Therapeutics' Debt to Equity's 5-year high stood at $0.93 during Q1 2015, with a 5-year trough of $0.05 in Q3 2019.
- Its 5-year average for Debt to Equity is $0.3, with a median of $0.23 in 2018.
- In the last 5 years, Fate Therapeutics' Debt to Equity skyrocketed by 327225.72% in 2015 and then crashed by 8090.4% in 2017.
- Over the past 5 years, Fate Therapeutics' Debt to Equity (Quarter) stood at $0.48 in 2015, then tumbled by 69.76% to $0.15 in 2016, then skyrocketed by 31.31% to $0.19 in 2017, then crashed by 51.65% to $0.09 in 2018, then plummeted by 43.96% to $0.05 in 2019.
- Its Debt to Equity stands at $0.05 for Q3 2019, versus $0.12 for Q2 2019 and $0.1 for Q1 2019.